# Efficacy of MND-2119 in Participants With Hypertriglyceridemia

> **NCT03693131** · PHASE3 · COMPLETED · sponsor: **Mochida Pharmaceutical Company, Ltd.** · enrollment: 580 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** Icosapent (MND-2119)
- **DRUG:** Icosapent (EPADEL CAPSULES 300)

## Key facts

- **NCT ID:** NCT03693131
- **Lead sponsor:** Mochida Pharmaceutical Company, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-27
- **Primary completion:** 2019-06-15
- **Final completion:** 2019-06-29
- **Target enrollment:** 580 (ACTUAL)
- **Last updated:** 2019-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03693131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03693131, "Efficacy of MND-2119 in Participants With Hypertriglyceridemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03693131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*